We work to understand ways in which our practice areas, Value, Access, and Pricing (VAP) and Commercial Planning (CP), intersect and influence each other in the early pipeline stages.
Showing 1 of 1 posts
May 25, 2021 | Blogs
Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.